Circulating Non-coding RNAs and Cardiovascular Outcomes in Patients With Dyslipidemia and Atherosclerosis
NCT ID: NCT03279770
Last Updated: 2017-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2015-06-30
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
While the roles of lncRNAs in human diseases including cancer and neurodegenerative disorders are beginning to emerge, it remains unclear how lncRNA regulation contributes to atherosclerotic vascular diseases in patients with dyslipidemia. In this proposal, we seek to apply next-generation sequencing technology to investigate circulating (plasma and peripheral blood mononuclear cells \[PBMC\]) lncRNA expression in control subjects and in dyslipidemic patients with and without atherosclerotic vascular diseases (CAD, ischemic stroke and PAOD). The results from these experiments will lead to better understanding of how circulating lncRNAs contribute to atherosclerotic cardiovascular complications.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It has become increasingly clear that the transcription of the eukaryotic genome is far more pervasive and complex than previously appreciated. While the expression of messenger RNAs (mRNAs) and microRNAs (miRNAs) account for only \~1% of all transcribed species, up to 90% of the mammalian genome is transcribed as long non-coding RNAs (lncRNAs), a heterogeneous group of non-coding transcripts longer than 200 nucleotides. LncRNAs have been shown to be functional and involved in specific physiological and pathological processes through epigenetic, transcriptional and post-transcriptional mechanisms. While the roles of lncRNAs in human diseases including cancer and neurodegenerative disorders are beginning to emerge, it remains unclear how lncRNA regulation contributes to atherosclerotic vascular diseases in patients with dyslipidemia.
In this proposal, we seek to apply next-generation sequencing technology to investigate circulating (plasma and peripheral blood mononuclear cells \[PBMC\]) lncRNA expression in control subjects and in dyslipidemic patients with and without atherosclerotic vascular diseases (CAD, ischemic stroke and PAOD). We will test the hypothesis that circulating lncRNA expression signature can reflect the atherosclerotic disease states in patients with dyslipidemia. A gene co-expression network analysis will be conducted to identify lncRNAs that are functionally involved in the pathogenesis of atherosclerosis. With the experimental results from an initial dyslipidemic cohort, we will establish an atherosclerosis scoring model on the basis of circulating lncRNA expression signature to facilitate the detection of atherosclerotic vascular diseases in patients with dyslipidemia. The accuracy, sensitivity and specificity of the lncRNA-based atherosclerosis scoring system will then be tested in an independent, large validation cohort. Next, we propose to test the hypothesis that circulating lncRNAs can be novel prognostic biomarkers to predict atherosclerosis progression and cardiovascular outcomes in dyslipidemic patients. The results from these experiments will lead to better understanding of how circulating lncRNAs contribute to atherosclerotic cardiovascular complications. These studies will also establish a set of novel, lncRNA-based diagnostic and prognostic biomarker in dyslipidemic patients to improve clinical preventive and therapeutic care. In addition, the findings from these studies will help to develop novel therapeutic strategies to treat or prevent atherosclerotic vascular diseases in patients with dyslipidemia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Atherosclerotic vascular disease:
1. Coronary atherosclerosis as evidenced by cardiac catheterization examination, having history of myocardial infarction as evidenced by ECG or hospitalization, angina patient showing ischemic ECG changes or positive response to stress test;
2. Cerebral vascular disease, cerebral infarction, intracerebral hemorrhage (excluding intracerebral hemorrhage associated with other diseases); transient ischemic attack (TIA) with carotid artery ultrasound confirming atheromatous change with more than 70% blockage;
3. Peripheral atherosclerosis with symptoms of ischemia and confirmed by Doppler ultrasound or angiography in history.
3. Control subjects: Age, gender-matched healthy adults without dyslipidemia and atherosclerotic diseases will be recruited as control subjects.
20 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chau-Chung Wu, M.D., Ph. D.
Role: PRINCIPAL_INVESTIGATOR
National Taiwan University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Taiwan University Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201505165RINC
Identifier Type: -
Identifier Source: org_study_id